Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2016 May;16(5):565-575.
doi: 10.1016/S1473-3099(15)00536-8. Epub 2016 Jan 29.

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

Collaborators
Multicenter Study

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

TenoRes Study Group. Lancet Infect Dis. 2016 May.

Erratum in

  • Corrections.
    [No authors listed] [No authors listed] Lancet Infect Dis. 2016 Jun;16(6):636. doi: 10.1016/S1473-3099(16)30089-5. Epub 2016 Jun 15. Lancet Infect Dis. 2016. PMID: 27301917 Free PMC article. No abstract available.
  • Corrections.
    [No authors listed] [No authors listed] Lancet Infect Dis. 2018 Jan;18(1):21. doi: 10.1016/S1473-3099(17)30723-5. Epub 2017 Dec 20. Lancet Infect Dis. 2018. PMID: 31787204 No abstract available.

Abstract

Background: Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat and prevent HIV, although few data exist for frequency and risk factors of acquired drug resistance in regions hardest hit by the HIV pandemic. We aimed to do a global assessment of drug resistance after virological failure with first-line tenofovir-containing ART.

Methods: The TenoRes collaboration comprises adult HIV treatment cohorts and clinical trials of HIV drug resistance testing in Europe, Latin and North America, sub-Saharan Africa, and Asia. We extracted and harmonised data for patients undergoing genotypic resistance testing after virological failure with a first-line regimen containing tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleotide reverse-transcriptase inhibitor (NNRTI; efavirenz or nevirapine). We used an individual participant-level meta-analysis and multiple logistic regression to identify covariates associated with drug resistance. Our primary outcome was tenofovir resistance, defined as presence of K65R/N or K70E/G/Q mutations in the reverse transcriptase (RT) gene.

Findings: We included 1926 patients from 36 countries with treatment failure between 1998 and 2015. Prevalence of tenofovir resistance was highest in sub-Saharan Africa (370/654 [57%]). Pre-ART CD4 cell count was the covariate most strongly associated with the development of tenofovir resistance (odds ratio [OR] 1·50, 95% CI 1·27-1·77 for CD4 cell count <100 cells per μL). Use of lamivudine versus emtricitabine increased the risk of tenofovir resistance across regions (OR 1·48, 95% CI 1·20-1·82). Of 700 individuals with tenofovir resistance, 578 (83%) had cytosine analogue resistance (M184V/I mutation), 543 (78%) had major NNRTI resistance, and 457 (65%) had both. The mean plasma viral load at virological failure was similar in individuals with and without tenofovir resistance (145 700 copies per mL [SE 12 480] versus 133 900 copies per mL [SE 16 650; p=0·626]).

Interpretation: We recorded drug resistance in a high proportion of patients after virological failure on a tenofovir-containing first-line regimen across low-income and middle-income regions. Effective surveillance for transmission of drug resistance is crucial.

Funding: The Wellcome Trust.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Countries contributing data to resistance analysis and HIV-1 subtype distribution, (B) prevalence of drug resistance by mutation and by region NNRTI=non-nucleotide reverse-transcriptase inhibitor. TDF=tenofovir disoproxil fumarate. *24% (n=462) of participants had tenofovir resistance when genotypes from viral load >1000 copies HIV-1 RNA per mL were considered.
Figure 2
Figure 2
Pooled odds ratios for tenofovir resistance after viral failure for baseline CD4 cell count <100 vs ≥100 × 106 cells per μL TDF+ denotes presence of tenofovir resistance. TDF=tenofovir disoproxil fumarate.
Figure 3
Figure 3
Odds ratios for NNRTI resistance for (A) baseline CD4 cell count <100 vs ≥100 cells per μL, (B) viral load ≥100 000 vs <100 000 copies HIV-1 RNA per mL NNRTI=non-nucleotide reverse-transcriptase inhibitor.
Figure 4
Figure 4
Boxplot of log viral load by presence (TDF-positive) or absence (TDF-negative) of tenofovir resistance at viral failure in studies with at least ten patients with TDF resistance and a viral load measurement at treatment failure We restricted to studies with at least ten TDF-resistant mutations to help with graphical clarity, although the pattern of similar distributions of failure viral load in the presence or absence of TDF resistance was true for all studies. TDF=tenofovir disoproxil fumarate. Blue dots represent outliers.

Comment in

References

    1. UNAIDS World AIDS Day 2014 Report - fact sheet. 2014. http://www.unaids.org/en/resources/campaigns/World-AIDS-Day-Report-2014/... (accessed May 7, 2015).
    1. WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection 2013. http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html (accessed July 14, 2015). - PubMed
    1. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57. - PubMed
    1. Hankins CA, Dybul MR. The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review. Curr Opin HIV AIDS. 2013;8:50–58. - PubMed
    1. Garforth SJ, Lwatula C, Prasad VR. The lysine 65 residue in HIV-1 reverse transcriptase function and in nucleoside analog drug resistance. Viruses. 2014;6:4080–4094. - PMC - PubMed

Publication types

MeSH terms